Optimized human cell products for research
and drug discovery

News & Events

DefiniGEN announces collaboration with GenoMembrane to further develop iPS-derived intestinal organoids for drug absorption and transportation assay models

Posted on

Cambridge UK – 8th December 2017 – DefiniGEN the world leader in human iPSC differentiation and disease modelling using CRISPR gene-editing technology, announce the launch of their business collaboration with GenoMembrane Co.,Ltd., a Yokohama-based company who specializes in drug-transported related technology and supply a wide variety of drug transporter assay kits to pharmaceutical companies worldwide. […]

ELRIG Drug Discovery 2017 Conference, 3-4th October 2017

Posted on

Visit DefiniGEN Stand iZ6 at ELRIG Drug Discovery 2017 Conference, 3-4th October 2017 ELRIG Drug Discovery conference will be held at the ACC in Liverpool from 3-4th October.  Please visit: https://elrig.org/portfolio/elrig-2017-events-programme/. DefiniGEN will be in the innovation zone at stand iZ6, which is located in ACC Hall 2. About DefiniGEN: DefiniGEN has world-leading expertise in […]

Join DefiniGEN at BioJapan 2017 Yokohama 11-13 October Booth C49

Posted on

Join DefiniGEN at BioJapan 2017 Yokohama 11-13 October Booth C49 DefiniGEN and Kishida Chemical will co-exhibit at Bio Japan 2017. DefiniGEN will launch its exciting product portfolio to the Japanese market. This includes: Human iPSC-Derived Pancreatic Beta Cells, wild-type Human iPSC-Derived hepatocytes, Human iPSC-Derived Alpha-one antitrypsin deficiency hepatocytes and recently developed Human iPS-Derived Intestinal Organoids. […]

DefiniGEN announces collaboration with Kishida Chemical to develop their iPSC-derived disease model business in the Japanese pharmaceutical market

Posted on

Cambridge UK – August, 2017 – DefiniGEN, the world leader in human iPSC differentiation and disease modelling using CRISPR gene-editing technology, announce the launch of their business partnership with Kishida Chemical who supply a wide variety of chemical compound libraries to Japanese pharmaceutical companies. DefiniGEN’s custom made disease models can be applied to various applications […]

DefiniGEN Licenses Cholangiocyte Stem Cell Technology from Cambridge Enterprise

Posted on

Cambridge, UK, 26 April 2017: DefiniGEN, a leading provider of stem cell products and services, today announced that it has strengthened its IP portfolio with a licence for cutting-edge cholangiocyte liver technology from Cambridge Enterprise, the commercialisation arm of the University of Cambridge. The technology will be used by DefiniGEN to develop optimised liver cell […]